Literature DB >> 16214528

Persistence of marrow stromal cells implanted into acutely infarcted myocardium: observations in a xenotransplant model.

Derek J MacDonald1, Jun Luo, Takayuki Saito, Minh Duong, Pierre-Luc Bernier, Ray C J Chiu, Dominique Shum-Tim.   

Abstract

OBJECTIVE: It has been reported that unmatched adult bone marrow stromal cells could be tolerated by immune-competent allotransplant or xenotransplant recipients under various conditions. This study examined whether xenogeneic bone marrow stromal cells implanted immediately after myocardial infarction can survive and differentiate, attenuating deterioration in left ventricular function.
METHODS: In groups I and II (n = 34), myocardial infarctions were created in immunocompetent adult Lewis rats by proximal left coronary artery ligation. In group I, 3 x 10(6)lacZ-labeled mouse bone marrow stromal cells were immediately injected into the peri-infarct area of the left ventricle, whereas in group II, only culture medium was injected. There were 10 early and 4 late deaths. At 4 weeks after injection, hearts were stained for beta-galactosidase and troponin IC. In groups IIIA and IIIB, lacZ-labeled mouse skin fibroblasts were implanted into rat myocardium (n = 10 each) with and without left coronary artery ligation, respectively, and the rats were killed serially. In group IV, animals underwent sham surgery (n = 5, no deaths). At 4 weeks, surviving rats in groups I, II, and IV (n = 10, n = 10, and n = 5, respectively) underwent blinded transthoracic echocardiography for ventricular function studies.
RESULTS: In group I, labeled mouse-derived bone marrow stromal cells were found within rat myocardium that stained positively for troponin IC 4 weeks after implantation. Functionally, mean left ventricular ejection fraction (P = .007), stroke volume (P = .03), and fractional shortening (P = .02) were all significantly higher in group I than in group II. In groups IIIA and IIIB, mouse fibroblasts induced cellular infiltration with rapid loss of donor cells. No labeled cells were found after 4 days. In group IV, there was no change in cardiac function.
CONCLUSION: Xenogeneic bone marrow stromal cells implanted into acutely ischemic myocardium induced by coronary artery ligation were immunologically tolerated, survived and differentiated, resulting in a cardiac chimera which improved left ventricular function. This unique immunologic tolerance may suggest the feasibility of using bone marrow stromal cells as universal donor cells.

Entities:  

Mesh:

Year:  2005        PMID: 16214528     DOI: 10.1016/j.jtcvs.2005.04.033

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  17 in total

1.  Can mesenchymal stem cells induce tolerance to cotransplanted human embryonic stem cells?

Authors:  Etienne Puymirat; Raghed Geha; André Tomescot; Valérie Bellamy; Jérôme Larghero; Ludovic Trinquart; Patrick Bruneval; Michel Desnos; Albert Hagège; Michel Pucéat; Philippe Menasché
Journal:  Mol Ther       Date:  2008-10-07       Impact factor: 11.454

2.  Transplanted xenogenic bone marrow stem cells survive and generate new bone formation in the posterolateral lumbar spine of non-immunosuppressed rabbits.

Authors:  Hyung-Jun Kim; Jong-Beom Park; Jin Kyung Lee; Eun-Young Park; Eun-Ae Park; K Daniel Riew; Seung-Koo Rhee
Journal:  Eur Spine J       Date:  2008-09-25       Impact factor: 3.134

Review 3.  Can the outcomes of mesenchymal stem cell-based therapy for myocardial infarction be improved? Providing weapons and armour to cells.

Authors:  Andrey A Karpov; Daria V Udalova; Michael G Pliss; Michael M Galagudza
Journal:  Cell Prolif       Date:  2016-11-23       Impact factor: 6.831

Review 4.  Allogeneic and xenogeneic transplantation of adipose-derived stem cells in immunocompetent recipients without immunosuppressants.

Authors:  Ching-Shwun Lin; Guiting Lin; Tom F Lue
Journal:  Stem Cells Dev       Date:  2012-07-03       Impact factor: 3.272

5.  Postinfarct intramyocardial injection of mesenchymal stem cells pretreated with TGF-alpha improves acute myocardial function.

Authors:  Jeremy L Herrmann; Aaron M Abarbanell; Brent R Weil; Yue Wang; Jeffrey A Poynter; Mariuxi C Manukyan; Daniel R Meldrum
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-05-19       Impact factor: 3.619

6.  Transplantation of cardiac progenitor cell sheet onto infarcted heart promotes cardiogenesis and improves function.

Authors:  Liudmila Zakharova; Diego Mastroeni; Nezahet Mutlu; Michelle Molina; Steven Goldman; Edward Diethrich; Mohamed A Gaballa
Journal:  Cardiovasc Res       Date:  2010-01-29       Impact factor: 10.787

7.  Comparative study of three types of polymer materials co-cultured with bone marrow mesenchymal stem cells for use as a myocardial patch in cardiomyocyte regeneration.

Authors:  Hongxing Niu; Junsheng Mu; Jianqun Zhang; Ping Hu; Ping Bo; Yan Wang
Journal:  J Mater Sci Mater Med       Date:  2013-04-26       Impact factor: 3.896

8.  Female stem cells are superior to males in preserving myocardial function following endotoxemia.

Authors:  Mariuxi C Manukyan; Brent R Weil; Yue Wang; Aaron M Abarbanell; Jeremy L Herrmann; Jeffrey A Poynter; Benjamin D Brewster; Daniel R Meldrum
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-03-30       Impact factor: 3.619

9.  Human Umbilical Cord Blood for Transplantation Therapy in Myocardial Infarction.

Authors:  Sandra A Acosta; Nick Franzese; Meaghan Staples; Nathan L Weinbren; Monica Babilonia; Jason Patel; Neil Merchant; Alejandra Jacotte Simancas; Adam Slakter; Mathew Caputo; Milan Patel; Giorgio Franyuti; Max H Franzblau; Lyanne Suarez; Chiara Gonzales-Portillo; Theo Diamandis; Kazutaka Shinozuka; Naoki Tajiri; Paul R Sanberg; Yuji Kaneko; Leslie W Miller; Cesar V Borlongan
Journal:  J Stem Cell Res Ther       Date:  2013-07-01

Review 10.  Concise review: immunomodulatory properties of mesenchymal stem cells in cellular transplantation: update, controversies, and unknowns.

Authors:  Rony Atoui; Ray C J Chiu
Journal:  Stem Cells Transl Med       Date:  2012-03-12       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.